Echinocandins in the management of invasive fungal infections, part 1

American Journal of Health-System Pharmacy

Volumn 63, Issue 18, 2006, Pages 1693-1703

  Morris, Michele I ^a   Villmann, Mark ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Infectious Diseases Division   (United States)

Author keywords

Anidulafungin; Antifungals; Caspofungin; Combined therapy; Concentration; Costs; Dosage; Drug administration; Drug interactions; Mechanism of action; Micafungin; Mycoses; Pharmacodynamics; Pharmacokinetics; Resistance; Spectrum microbial; Toxicity

Indexed keywords

1,3 BETA GLUCAN SYNTHASE; AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CARBAMAZEPINE; CASPOFUNGIN; CREATININE; CYCLOSPORIN; CYTOCHROME P450 3A4; DEXAMETHASONE; DIPHENHYDRAMINE; ECHINOCANDIN; EFAVIRENZ; FLUCONAZOLE; GLUCAN SYNTHASE INHIBITOR; HMR 3270; HYDROCORTISONE; ITRACONAZOLE; MICAFUNGIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEVIRAPINE; NIFEDIPINE; PHENYTOIN; PREDNISOLONE; RAPAMYCIN; RIFAMPICIN; TACROLIMUS; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORICONAZOLE;

ABDOMINAL PAIN; ANAPHYLAXIS; ASPERGILLUS; CANDIDA; CHILL; CLINICAL TRIAL; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; DIARRHEA; DOSE RESPONSE; DRUG CROSS REACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RESISTANCE; DYSPNEA; ENZYME INHIBITION; ESOPHAGUS CANDIDIASIS; FACE EDEMA; FEBRILE NEUTROPENIA; FEVER; FUNGICIDAL ACTIVITY; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTENSIVE CARE; LEUKOPENIA; LIVER DYSFUNCTION; MAMMAL CELL; MYCOSIS; NAUSEA; NEUTROPENIA; PHLEBITIS; PRIORITY JOURNAL; RASH; REVIEW; STRIDOR; SWELLING; SYSTEMATIC REVIEW; UREA NITROGEN BLOOD LEVEL; VASODILATATION; VOMITING;

EID: 33748792061     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp050464.p1     Document Type: Review

References (62)

1. McNeil MM, Nash SL, Hajjeh RA et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis. 2001; 33:641-7.
2. Bille J, Marchetti O, Calandra T. Changing face of health-care associated fungal infections. Curr Opin Infect Dis. 2005; 18:314-9.
3. Trick WE, Fridkin SK, Edwards JR et al. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis. 2002; 35:627-30.
4. Pfaller MA, Diekema DJ, for the International Fungal Surveillance Group. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect. 2004; 10(suppl 1):11-23.
5. Drago M, Scaltrito MM, Cariani L et al. In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei. Eur J Clin Microbiol Infect Dis. 2004; 23:619-24.
6. Marr KA, Carter RA, Grippa F et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002; 34:909-17.
7. Arathoon EG. Clinical efficacy of echinocandin antifungals. Curr Opin Infect Dis. 2001; 14:685-91.
8. Debono M, Gordee RS. Antibiotics that inhibit fungal cell wall development. Annu Rev Microbiol. 1994; 48:471-97.
9. Wiederhold NP, Lewis RE. The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy. Expert Opin Investig Drugs. 2003; 12:1313-33.
10. Denning DW. Echinocandin antifungal drugs. Lancet. 2003; 362:1142-51.
11. Odds FC, Brown AJ, Gow NA. Antifungal agents: mechanisms of action. Trends Microbiol 2003; 11:272-9.
12. Zaas AK, Alexander BD, Echinocandins: role in antifungal therapy, 2005. Expert Opin Pharmacother. 2005; 6:1657-68.
13. Gomez BL, Nosanchuk JD. Melanin and fungi. Curr Opin Infect Dis. 2003;16:91-6.
14. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol. 2003; 20:121-36.
15. Del Poeta M, Schell WA, Perfect JR. In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob Agents Chemother. 1997; 41:1835-6.
16. Kurtz MB, Heath IB, Marrinan J et al. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrob Agents Chemother. 1994; 38:1480-9.
17. Odabasi Z, Paetznick VL, Rodriguez JR et al. In vitro activity of anidulafungin against selected clinically important mould isolates. Antimicrob Agents Chemother. 2004; 48:1912-5.
18. Kartsonis N, Killar J, Mixson L et al. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome. Antimicrob Agents Chemother. 2005; 49:3616-23.
19. Moudgal V, Little T, Boikov D et al. Multiechinocandin and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother. 2005; 49:767-9.
20. Hernandez S, Lopez-Ribot JL, Najvar LK et al. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother. 2004; 48:1382-3.
21. Park S, Kelly R, Kahn JN et al. Specific substitutions in the echinocandin target Fkslp account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother. 2005; 49:3264-73.
22. Schuetzer-Muehlbauer M, Willinger B, Krapf G et al. The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to Caspofungin. Mol Microbiol. 2003; 48:225-35.
23. Osherov N, May GS, Albert ND et al. Overexpression of Sbe2p, a Golgi protein, results in resistance to caspofungin in Saccharomyces cerevisiae. Antimicrob Agents Chemother. 2002; 46:2462-9.
24. Andes D, Marchillo K, Lowther J et al. In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model. Antimicrob Agents Chemother. 2003; 47:1187-92.
25. Theuretzbacher U. Pharmacokinetics/pharmacodynamics of echinocandins. Eur J Clin Microbiol Infect Dis. 2004; 23:805-12.
26. Vasquez J. Anidulafungin: a new echinocandin with a novel profile. Clin Ther. 2005; 27:657-73.
27. Stone J, Holland SD, Wickersham PJ et al. Single- and multiple-dose pharmacokinetics of Caspofungin in healthy men. Antimicrob Agents Chemother. 2002; 46:739-45.
28. Caspofungin package insert. Whitehouse Station, NJ: Merck & Co.; 2005 Feb.
29. Stone J, Xu X, Winchell G et al. Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother. 2004; 48:815-23.
30. Micafungin package insert. Deerfield, IL: Astellas Pharma US; 2005 Apr.
31. Hiemenz J, Cagnoni P, Simpson D et al. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother. 2005; 49:1331-6.
32. Villanueva A, Arathoon EG, Gotuzzo E et al. A randomized, double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis. 2001; 33:1529-35.
33. Arathoon EG, Gotuzzo E, Noriega LM et al. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiasis. Antimicrob Agents Chemother. 2002; 46:451-7.
34. Villanueva A, Gotuzzo E, Arathoon EG et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med. 2002; 113:294-9.
35. Pettengell K, Mynhardt J, Kluyts T et al. Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment Pharmacol Ther. 2004;20:475-81.
36. De Wet N, Llanos-Cuentas A, Suleiman J et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis. 2004; 39:842-9.
37. De Wet NT, Bester AJ, Viljoen JJ et al. A randomized, double-blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther. 2005; 21:899-907.
38. Kohno S, Masaoka T, Yamaguchi H et al. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycoses in Japan. Scand J Infect Dis. 2004; 36:372-9.
39. Nonoyama M, Kume H, Kumagai K et al. [A successful treatment with micafungin of candidemia due to Candida krusei. J Kansenshogaku Zasshi. 2003; 77:982-5. In Japanese.
40. Kanada M, Imaoka H, Oshita Y et al. [Successful treatment with micafungin in a case of candidemia associated with pneumonia.] Kansenshogaku Zasshi. 2005; 79:284-9. In Japanese.
41. Ruhnke M, Kuse E, Chetchotisakd P et al. Comparison of micafungin and liposomal amphotericin B for invasive candidiasis. Paper presented at 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; 2005 Dec 17.
42. Astellas Pharma US. Study of micafungin in patients with invasive candidiasis or candidemia, www.clinicaltrials.gov (accessed 2005 Jul 25).
43. Krause DS, Simjee AE, van Rensburg C et al. A randomized double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis. 2004; 39:770-5.
44. Laine L. The natural history of esophageal candidiasis after successful treatment in patients with AIDS. Gastroenterology. 1994; 107:744-6.
45. Vasquez J, Schranz J, Krause D et al. Efficacy of anidulafungin in patients with azole-refractory mucosal candidiasis. Paper presented at Focus on Fungal Infections 15 meeting. Miami, FL; 2005 Mar 17.
46. Viljoen J, Schranz J, Krause D et al. Efficacy of anidulafungin vs. fluconazole in HIV negative patients with esophageal candidiasis. Paper presented at Focus on Fungal Infections 15 meeting. Miami, FL; 2005 Mar 17.
47. Schranz J, Krause D, Goldstein BP et al. Efficacy of anidulafungin for the treatment of candidemia. Paper presented at 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; 2003 Sep 15.
48. Krause DS, Reinhardt J, Vasquez JA et al. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother. 2004; 48:2021-4.
49. Reboli A, Rotstein C, Pappas P et al. Anidulafungin vs. fluconazole for treatment of candidemia and invasive candidiasis. Paper presented at 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; 2005 Dec 17.
50. Maertens J, Raad I, Petrikkos G et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis. 2004; 39:1563-71.
51. Kartsonis NA, Saah AJ, Lipka CJ et al. Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. J Infect. 2005; 50:196-205.
52. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2003; 347:2020-9.
53. Ullmann AJ, Van Burik JA, McSweeney P et al. An open phase II study of the efficacy of micafungin (FK 463) alone and in combination for the treatment of invasive aspergillosis (IA) in adults and children. Paper presented at 13th European Congress of Clinical Microbiology and Infectious Diseases. Glasgow, Scotland; 2003 May.
54. Yokote T, Akioka T, Oka S et al. Successful treatment with micafungin of invasive pulmonary aspergillosis in acute myeloid leukemia, with renal failure due to amphotericin B therapy. Ann Hematol. 2004; 83:64-6.
55. Ota S, Tanaka J, Kahata K et al. Successful micafungin (FK463) treatment of invasive pulmonary aspergillosis in a patient with acute lymphoblastic leukemia in a phase II study. Int J Hematol. 2004; 79:390-3.
56. Singer M, Seibel N, Vezina G et al. Successful treatment of invasive aspergillosis in two patients with acute myelogenous leukemia. J Pediatr Hematol Oncol. 2003; 25:252-6.
57. Eraxis (anidulafungin) for injection package insert. New York: Pfizer Inc.; 2006 Feb.
58. Kartsonis NA, Nielsen J, Douglas CM. Caspofungin: the first in a new class of antifungal agents. Drug Resist Updat. 2003; 6:197-218.
59. Hebert MF, Townsend RW, Austin S et al. Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol. 2005; 45:954-60.
60. Pfaller M. Anidulafungin: an echinocandin antifungal. Expert Opin Investig Drugs. 2004; 13:1183-97.
61. Dowell JA, Stogniew M, Krause D et al. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J Clin Pharmacol. 2005; 45:227-33.
62. Anidulafungin (Eraxis) for Candida infections. Med Lett Drugs Ther. 2006; 48:43-4.